Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
ConditionMigraine
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-70
SponsorMayo Clinic
About this trial
This goal of this study is to compare three medications used for migraine preventive treatment.
This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others.
Research participants will:
* Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits.
Eligibility criteria
Qualifiers
Adults, 18-70 years of age at the time of enrollment
Migraine with aura, migraine without aura, and/or chronic migraine; according to ICHD-3 diagnostic criteria. (Those with daily or continuous headaches are not excluded.)
Migraine onset prior to 50 years of age
Migraine present for at least 12 months at the time of enrollment
Disqualifiers
Contraindications to taking atogepant, propranolol, or topiramate.
Currently taking atogepant, propranolol, or topiramate*
Previously took atogepant, propranolol, or topiramate*
Unwillingness to take atogepant, topiramate, or propranolol.
Trial design
Treatments tested in this trial
- Atogepant 60 mg
- Propranolol 160 mg
- Topiramate 100 mg
Treatment groups
1,335 Participants
are divided into 3 treatment groupsSponsors and collaborators
Mayo Clinic
Lead sponsor
University of Iowa
Collaborator
Patient-Centered Outcomes Research Institute
Collaborator
AbbVie
Collaborator
Source ClinicalTrials.gov